Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription 04.10.2021 2 AJR Am J Roentgenol 2 Ann Surg 14 Ann Surg Oncol 3 Anticancer Res 4 BMC Cancer 9 Br J Cancer 3 Breast Cancer 1 Breast Cancer (Dove Med Press) 5 Breast Cancer Res 5 Breast Cancer Res Treat 1 Breast J 3 Cancer 2 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 2 Cancer Res 4 Clin Breast Cancer 2 Clin Cancer Res 1 Eur J Cancer 3 Eur J Surg Oncol 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Biol Chem 2 J Clin Invest 1 J Clin Oncol 7 J Natl Cancer Inst 2 Lancet Oncol 1 Mod Pathol 2 NPJ Breast Cancer 2 PLoS One 1 Radiother Oncol 1 Science

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. VIERS KN, Hunt LD
   Lymph Node Staging in Newly Diagnosed Breast Cancer: Point-Preoperative Staging Axillary Ultrasound is Valuable in the Contemporary Evaluation of Newly Diagnosed Breast Cancer.
   AJR Am J Roentgenol. 2021 Sep 29. doi: 10.2214/AJR.21.26812.
   PubMed        
   
   
2. BHOLE S, Friedewald SM
   Lymph Node Staging in Newly Diagnosed Breast Cancer: Counterpoint-Sentinel Biopsy Surpasses Axillary Imaging in Early-Stage Cancers, But Is the Sun Setting on This Controversy?
   AJR Am J Roentgenol. 2021 Sep 29. doi: 10.2214/AJR.21.26767.
   PubMed        
   
   

   
   Ann Surg

3. TOESCA A, Sangalli C, Maisonneuve P, Massari G, et al
   A Randomized Trial of Robotic Mastectomy versus Open Surgery in Women With Breast Cancer or BRCA Mutation.
   Ann Surg. 2021 Jun 9. pii: 00000658-900000000-93515.
   PubMed         Abstract available
   
   
4. KARAKAS C, Francis AM, Ha MJ, Wingate HF, et al
   Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer.
   Ann Surg. 2021;274:e150-e159.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. BYUN DJ, Wu SP, Nagar H, Gerber NK, et al
   Ductal Carcinoma in Situ in Young Women: Increasing Rates of Mastectomy and Variability in Endocrine Therapy Use.
   Ann Surg Oncol. 2021;28:6083-6096.
   PubMed         Abstract available
   
   
6. MOO TA, Saccarelli CR, Sutton EJ, Sevilimedu V, et al
   Tumor-Nipple Distance of >/= 1 cm Predicts Negative Nipple Pathology After Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2021;28:6024-6029.
   PubMed         Abstract available
   
   
7. SHAH C, Bremer T, Cox C, Whitworth P, et al
   The Clinical Utility of DCISionRT((R)) on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery.
   Ann Surg Oncol. 2021;28:5974-5984.
   PubMed         Abstract available
   
   
8. GORDON NT, Alberty-Oller JJ, Fei K, Greco G, et al
   Association of Insulin Resistance and Higher Oncotype DX Recurrence Score.
   Ann Surg Oncol. 2021;28:5941-5947.
   PubMed         Abstract available
   
   
9. VAN LA PARRA RFD, Clough KB, Thygesen HH, Levy E, et al
   Oncological Safety of Oncoplastic Level II Mammoplasties After Neoadjuvant Chemotherapy for Large Breast Cancers: A Matched-Cohort Analysis.
   Ann Surg Oncol. 2021;28:5920-5928.
   PubMed         Abstract available
   
   
10. HILLS N, Leslie M, Davis R, Crowell M, et al
    Prolonged Time from Diagnosis to Breast-Conserving Surgery is Associated with Upstaging in Hormone Receptor-Positive Invasive Ductal Breast Carcinoma.
    Ann Surg Oncol. 2021;28:5895-5905.
    PubMed         Abstract available
    
    
11. BUTLER PD, Morris MP, Momoh AO
    Persistent Disparities in Postmastectomy Breast Reconstruction and Strategies for Mitigation.
    Ann Surg Oncol. 2021;28:6099-6108.
    PubMed         Abstract available
    
    
12. RELATION T, Obeng-Gyasi S, Bhattacharyya O, Li Y, et al
    Racial Differences in Response to Neoadjuvant Chemotherapy: Impact on Breast and Axillary Surgical Management.
    Ann Surg Oncol. 2021;28:6489-6497.
    PubMed         Abstract available
    
    
13. MILLEN EC, Cavalcante FP, Zerwes F, Novita G, et al
    The Attitudes of Brazilian Breast Surgeons on Axillary Management in Early Breast Cancer-10 Years after the ACOSOG Z0011 Trial First Publication.
    Ann Surg Oncol. 2021 Sep 27. pii: 10.1245/s10434-021-10812.
    PubMed         Abstract available
    
    
14. KOELBEL V, Pfob A, Schaefgen B, Sinn P, et al
    Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients.
    Ann Surg Oncol. 2021 Sep 28. pii: 10.1245/s10434-021-10847.
    PubMed         Abstract available
    
    
15. GONZALEZ L, Sun C, Loscalzo M, Clark K, et al
    A Cross-Sectional Study of Distress Levels in Patients with Newly Diagnosed Breast Cancer: The Impact of Race, Ethnicity, and Language Preference.
    Ann Surg Oncol. 2021 Sep 28. pii: 10.1245/s10434-021-10561.
    PubMed         Abstract available
    
    
16. BREDBECK BC, Dossett LA
    ASO Author Reflections: Adding up the Costs of Low-Value Breast Cancer Care.
    Ann Surg Oncol. 2021 Sep 29. pii: 10.1245/s10434-021-10863.
    PubMed        
    
    
17. MILLEN EC, Cavalcante FP
    ASO Author Reflections: Positive Sentinel Lymph Node in Breast Cancer Surgery.
    Ann Surg Oncol. 2021 Sep 24. pii: 10.1245/s10434-021-10836.
    PubMed        
    
    
18. MUKHTAR RA, Hoskin TL, Habermann EB, Day CN, et al
    Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB).
    Ann Surg Oncol. 2021;28:5867-5877.
    PubMed         Abstract available
    
    

    
    Anticancer Res

19. FRIEDRICH RE, Madani E
    Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer.
    Anticancer Res. 2021;41:5081-5087.
    PubMed         Abstract available
    
    
20. TAKASHIMA T, Nishimura S, Kawajiri H, Mizuyama Y, et al
    An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
    Anticancer Res. 2021;41:5007-5014.
    PubMed         Abstract available
    
    
21. VAHAAHO N, Hakamies-Blomqvist L, Blomqvist C, Kellokumpu-Lehtinen PL, et al
    Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients.
    Anticancer Res. 2021;41:5045-5052.
    PubMed         Abstract available
    
    

    
    BMC Cancer

22. LEE J, Jung JH, Kim WW, Kang B, et al
    Short-term serial assessment of electronic patient-reported outcome for depression and anxiety in breast Cancer.
    BMC Cancer. 2021;21:1065.
    PubMed         Abstract available
    
    
23. LIN Y, Zhou X, Peng W, Wu J, et al
    Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
    BMC Cancer. 2021;21:1062.
    PubMed         Abstract available
    
    
24. ABEBE E, Tollesa T, Assefa M, Tilahun Z, et al
    Cognitive functioning and its associated factors among breast cancer patients on chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa Ethiopia: an institution-based comparative cross-sectional study.
    BMC Cancer. 2021;21:1052.
    PubMed         Abstract available
    
    
25. AKINYEMIJU T, Jones K, Gupta A, Oyekunle T, et al
    Association of body composition with odds of breast cancer by molecular subtype: analysis of the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Nigerian Women (MEND) study.
    BMC Cancer. 2021;21:1051.
    PubMed         Abstract available
    
    

    
    Br J Cancer

26. SHAABAN AM, Hilton B, Clements K, Provenzano E, et al
    Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.
    Br J Cancer. 2021;124:1009-1017.
    PubMed         Abstract available
    
    
27. ZENG Y, Gao W, Chen X, Shen K, et al
    Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
    Br J Cancer. 2021;124:975-981.
    PubMed         Abstract available
    
    
28. WINKLER C, Armenia J, Jones GN, Tobalina L, et al
    SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
    Br J Cancer. 2021;124:951-962.
    PubMed         Abstract available
    
    
29. BADVE SS, Cho S, Gokmen-Polar Y, Sui Y, et al
    Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast.
    Br J Cancer. 2021;124:1150-1159.
    PubMed         Abstract available
    
    
30. PAI BELLARE G, Saha B, Patro BS
    Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
    Br J Cancer. 2021;124:1260-1274.
    PubMed         Abstract available
    
    
31. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed         Abstract available
    
    
32. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    PubMed         Abstract available
    
    
33. WANG C, Hu K, Luo C, Deng L, et al
    Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy.
    Br J Cancer. 2021 Sep 27. pii: 10.1038/s41416-021-01549.
    PubMed         Abstract available
    
    
34. BIZOT A, Karimi M, Rassy E, Heudel PE, et al
    Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.
    Br J Cancer. 2021 Sep 29. pii: 10.1038/s41416-021-01555.
    PubMed         Abstract available
    
    

    
    Breast Cancer

35. TAIRA N, Kashiwabara K, Tsurutani J, Kitada M, et al
    Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01296.
    PubMed        
    
    
36. NOGUCHI M, Inokuchi M, Yokoi-Noguchi M, Morioka E, et al
    The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
    Breast Cancer. 2021 Sep 30. pii: 10.1007/s12282-021-01300.
    PubMed         Abstract available
    
    
37. KOH SJ, Ohsumi S, Takahashi M, Fukuma E, et al
    Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analys
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01299.
    PubMed        
    
    

    
    Breast Cancer (Dove Med Press)

38. WARDHANI BWK, Louisa M, Watanabe Y, Setiabudy R, et al
    TGF-beta-Induced TMEPAI Promotes Epithelial-Mesenchymal Transition in Doxorubicin-Treated Triple-Negative Breast Cancer Cells via SMAD3 and PI3K/AKT Pathway Alteration.
    Breast Cancer (Dove Med Press). 2021;13:529-538.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

39. IBRAHIM AM, Bilsland A, Rickelt S, Morris JS, et al
    A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.
    Breast Cancer Res. 2021;23:90.
    PubMed         Abstract available
    
    
40. IONKINA AA, Balderrama-Gutierrez G, Ibanez KJ, Phan SHD, et al
    Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer.
    Breast Cancer Res. 2021;23:93.
    PubMed         Abstract available
    
    
41. LEOCE NM, Jin Z, Kehm RD, Roh JM, et al
    Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer.
    Breast Cancer Res. 2021;23:91.
    PubMed         Abstract available
    
    
42. LIOU L, Kaptoge S, Dennis J, Shah M, et al
    Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study.
    Breast Cancer Res. 2021;23:94.
    PubMed         Abstract available
    
    
43. ZARE A, Postovit LM, Githaka JM
    Robust inflammatory breast cancer gene signature using nonparametric random forest analysis.
    Breast Cancer Res. 2021;23:92.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

44. HAQUE R, Chlebowski RT, Chen L
    Sleep medication use and risk of fractures in breast cancer survivors.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06392.
    PubMed         Abstract available
    
    
45. ROCQUE GB, Caston NE, Franks JA, Williams CP, et al
    Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06381.
    PubMed         Abstract available
    
    
46. THOREN L, Eriksson M, Lindh JD, Czene K, et al
    Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.
    Breast Cancer Res Treat. 2021 Sep 27. pii: 10.1007/s10549-021-06386.
    PubMed         Abstract available
    
    
47. SOLIMAN O, Lowery A, Kerin M
    Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06403.
    PubMed        
    
    
48. TEINTURIER R, Abou Ziki R, Kassem L, Luo Y, et al
    Reduced menin expression leads to decreased ERalpha expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
    Breast Cancer Res Treat. 2021 Sep 24. pii: 10.1007/s10549-021-06339.
    PubMed         Abstract available
    
    

    
    Breast J

49. MASOOD S
    Why women with an average risk for breast cancer undergo contralateral breast mastectomy? Does healthcare coverage matter?
    Breast J. 2021 Sep 28. doi: 10.1111/tbj.14293.
    PubMed        
    
    

    
    Cancer

50. FALKSON CI
    Adjuvant tamoxifen adherence in male patients with breast cancer: An ongoing challenge.
    Cancer. 2021 Oct 1. doi: 10.1002/cncr.33898.
    PubMed        
    
    
51. OKE O, Niu J, Chavez-MacGregor M, Zhao H, et al
    Adjuvant tamoxifen adherence in men with early-stage breast cancer.
    Cancer. 2021 Oct 1. doi: 10.1002/cncr.33899.
    PubMed         Abstract available
    
    
52. NIERENGARTEN MB
    Higher mortality risk in African American women with triple-negative breast cancer.
    Cancer. 2021;127:3712-3713.
    PubMed        
    
    

    
    Cancer Epidemiol Biomarkers Prev

53. TAN VY, Bull CJ, Biernacka KM, Teumer A, et al
    Investigation of the interplay between circulating lipids and IGF-I and relevance to breast cancer risk: an observational and Mendelian randomization study.
    Cancer Epidemiol Biomarkers Prev. 2021 Sep 28. pii: 1055-9965.EPI-21-0315.
    PubMed         Abstract available
    
    
54. OMOFUMA OO, Peterson LL, Turner DP, Merchant AT, et al
    Dietary Advanced Glycation End-Products (AGEs) and Mortality After Breast Cancer in the Women's Health Initiative (WHI).
    Cancer Epidemiol Biomarkers Prev. 2021 Sep 28. pii: 1055-9965.EPI-21-0610.
    PubMed         Abstract available
    
    

    
    Cancer Lett

55. YADAV P, Sharma P, Sundaram S, Venkatraman G, et al
    SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells.
    Cancer Lett. 2021;522:211-224.
    PubMed         Abstract available
    
    

    
    Cancer Res

56. LIU C, Qiang J, Deng Q, Xia J, et al
    ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression.
    Cancer Res. 2021 Sep 27. pii: 0008-5472.CAN-21-1337.
    PubMed         Abstract available
    
    
57. ZHAO X, Li J, Liu Z, Powers S, et al
    Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-2555.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

58. LORUSSO P, Hamilton E, Ma C, Vidula N, et al
    A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
    Clin Breast Cancer. 2021 Aug 20. pii: S1526-8209(21)00240.
    PubMed         Abstract available
    
    
59. RIBATTI D, Annese T, Tamma R
    Controversial role of mast cells in breast cancer tumor progression and angiogenesis.
    Clin Breast Cancer. 2021 Aug 31. pii: S1526-8209(21)00246.
    PubMed         Abstract available
    
    
60. TOORANG F, Sasanfar B, Esmaillzadeh A, Zendehdel K, et al
    Adherence to the DASH Diet and Risk of Breast Cancer.
    Clin Breast Cancer. 2021 Jul 31. pii: S1526-8209(21)00198.
    PubMed         Abstract available
    
    
61. LI J, Li Y, Cheng H
    Circ-RPPH1 knockdown retards breast cancer progression via miR-328-3p-mediated suppression of HMGA2.
    Clin Breast Cancer. 2021 Aug 31. pii: S1526-8209(21)00247.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

62. KUMTHEKAR P, Tang SC, Brenner AJ, Kesari S, et al
    ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-3258.
    PubMed         Abstract available
    
    
63. SANCHEZ-GUIXE M, Hierro C, Jimenez J, Viaplana C, et al
    High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1810.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

64. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

65. SCHOP SJ, Joosen MEM, Wolswijk T, Heuts EM, et al
    Quality of life after autologous fat transfer additional to prosthetic breast reconstruction in women after breast surgery: A systematic review.
    Eur J Surg Oncol. 2021;47:772-777.
    PubMed         Abstract available
    
    
66. MIYOSHI T, Yamaguchi S, Fujimoto H, Yoshioka S, et al
    A new method to optimize resection area using a radiation treatment planning system and deformable image registration for breast-conserving surgery after neoadjuvant chemotherapy.
    Eur J Surg Oncol. 2021;47:789-795.
    PubMed         Abstract available
    
    
67. DE ROOIJ L, Bosmans JWAM, van Kuijk SMJ, Vissers YLJ, et al
    A systematic review of seroma formation following drain-free mastectomy.
    Eur J Surg Oncol. 2021;47:757-763.
    PubMed         Abstract available
    
    

    
    Int J Cancer

68. ZHANG L, Wu ZY, Li J, Lin Y, et al
    Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART): Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial.
    Int J Cancer. 2021 Sep 30. doi: 10.1002/ijc.33830.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

69. WENG JK, Lei X, Schlembach P, Bloom ES, et al
    Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation.
    Int J Radiat Oncol Biol Phys. 2021;111:360-370.
    PubMed         Abstract available
    
    

    
    J Biol Chem

70. MANNE RK, Agrawal Y, Malonia SK, Banday S, et al
    FBXL20 promotes breast cancer malignancy by inhibiting apoptosis through degradation of PUMA and BAX.
    J Biol Chem. 2021 Sep 26:101253. doi: 10.1016/j.jbc.2021.101253.
    PubMed         Abstract available
    
    

    
    J Clin Invest

71. KARTHIKEYAN S, Waters IG, Dennison L, Chu D, et al
    Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones.
    J Clin Invest. 2021;131.
    PubMed         Abstract available
    
    
72. MUSCARELLA AM, Aguirre S, Hao X, Waldvogel SM, et al
    Exploiting bone niches: progression of disseminated tumor cells to metastasis.
    J Clin Invest. 2021;131.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

73. DE RUITER MB, Reneman L, Kieffer JM, Oldenburg HSA, et al
    Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
    J Clin Oncol. 2021 Sep 30:JCO2100627. doi: 10.1200/JCO.21.00627.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

74. KAPOOR PM, Mavaddat N, Choudhury PP, Wilcox AN, et al
    Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.
    J Natl Cancer Inst. 2021;113:329-337.
    PubMed         Abstract available
    
    
75. FRANZOI MA, Eiger D, Ameye L, Ponde N, et al
    Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
    J Natl Cancer Inst. 2021;113:462-470.
    PubMed         Abstract available
    
    
76. MAGBANUA MJM, Hendrix LH, Hyslop T, Barry WT, et al
    Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
    J Natl Cancer Inst. 2021;113:443-452.
    PubMed         Abstract available
    
    
77. MAGUIRE S, Perraki E, Tomczyk K, Jones ME, et al
    Common Susceptibility Loci for Male Breast Cancer.
    J Natl Cancer Inst. 2021;113:453-461.
    PubMed         Abstract available
    
    
78. VAN DEN BROEK JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, et al
    Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
    J Natl Cancer Inst. 2021;113:434-442.
    PubMed         Abstract available
    
    
79. O'LEARY B, Cutts RJ, Huang X, Hrebien S, et al
    Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    J Natl Cancer Inst. 2021;113:309-317.
    PubMed         Abstract available
    
    
80. SPRAGUE BL, Lowry KP, Miglioretti DL, Alsheik N, et al
    Changes in Mammography Use by Women's Characteristics During the First 5 Months of the COVID-19 Pandemic.
    J Natl Cancer Inst. 2021;113:1161-1167.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

81. OMAR A, Arafat W
    HER2-low-positive breast cancer from four neoadjuvant clinical trials.
    Lancet Oncol. 2021;22:e426.
    PubMed        
    
    
82. DENKERT C, Nekljudova V, Loibl S
    HER2-low-positive breast cancer from four neoadjuvant clinical trials - Authors' reply.
    Lancet Oncol. 2021;22:e427.
    PubMed        
    
    

    
    Mod Pathol

83. FERGUSON DC, Mata DA, Tay TK, Traina TA, et al
    Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations.
    Mod Pathol. 2021 Sep 30. pii: 10.1038/s41379-021-00924.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

84. PETERLONGO P, Figlioli G, Deans AJ, Couch FJ, et al
    Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer.
    NPJ Breast Cancer. 2021;7:130.
    PubMed        
    
    
85. GYAMFI J, Yeo JH, Kwon D, Min BS, et al
    Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer.
    NPJ Breast Cancer. 2021;7:129.
    PubMed         Abstract available
    
    

    
    PLoS One

86. HADJIPANTELI A, Polyviou P, Kyriakopoulos I, Genagritis M, et al
    Comparison of two-view versus single-view digital breast tomosynthesis and 2D-mammography in breast cancer surveillance imaging.
    PLoS One. 2021;16:e0256514.
    PubMed         Abstract available
    
    
87. SANI L, Vispa A, Loretoni R, Duranti M, et al
    Breast lesion detection through MammoWave device: Empirical detection capability assessment of microwave images' parameters.
    PLoS One. 2021;16:e0250005.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

88. KAIDAR-PERSON O, Dahn HM, Nichol AM, Boersma LJ, et al
    A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer.
    Radiother Oncol. 2021 Sep 23. pii: S0167-8140(21)06735.
    PubMed         Abstract available
    
    

    
    Science

89. KIM M, Park J, Bouhaddou M, Kim K, et al
    A protein interaction landscape of breast cancer.
    Science. 2021;374:eabf3066.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: